Stada evaluates a roughly €6 billion bid for French consumer‑health business Copper Consumer Health, signalling a major push into European OTC markets
Executive summary: Stada is examining a potential acquisition of French consumer‑health firm Copper Consumer Health for about six billion euros, according to a Handelsblatt report. The deal would markedly enlarge Stada’s OTC business, reshape the European consumer‑health landscape and likely attract antitrust review. Stada (German generics manufacturer), Copper Consumer Health (French OTC pharmaceutical company), and relevant antitrust authorities in Germany, France and the EU. Stada may proceed with due diligence, file a formal offer, and seek clearance from competition regulators; if talks fail, the expansion plan could shift to other targets.
According to a media report cited by Handelsblatt, German generics maker Stada is examining the acquisition of Copper Consumer Health, a French over‑the‑counter pharmaceutical firm, for about six billion euros. Stada had previously announced an expansion strategy focused on consumer health assets. The deal, if completed, would reshape Stada’s portfolio and trigger antitrust scrutiny in both Germany and France. No official confirmation from either company has been issued yet.
Connected developments
- Pharma: „Wir führen derzeit Gespräche mit der Regierung“: US-Konzern Moderna prüft Kauf von Biontech-Werken
Open the full case file on Beyond →
Social Pulse
AI estimate · not scraped